All patients
age >= 55 yr age >= 60 yr age >= 65 yr autoimmune disease corticosteroids: no corticosteroids: yes critical disease invasive ventilation no oxygen needed non invasive oxygen omicron variant BA.1 (B.1.1.529) severe disease solid organ transplant recipients subjects at risk
anti-inflammatoty and immuno-therapy in COVID 19 all comers - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results LIFESAVER, 2021 2.00 [0.16; 24.66]
RECOVERY, 2022 0.87 [0.77; 0.98]
Tang X, 2020 0.98 [0.93; 1.02]
0.94 [0.85 ; 1.03 ] LIFESAVER, 2021, RECOVERY, 2022, Tang X, 2020 3 42% 8,254 moderate not evaluable death or transfer to ICUdetailed results BACC Bay Tocilizumab Trial, 2020 0.97 [0.50; 1.88]
0.97 [0.50 ; 1.88 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable deathsdetailed results BACC Bay Tocilizumab Trial, 2020 1.52 [0.41; 5.62]
LIFESAVER, 2021 2.00 [0.16; 24.66]
RECOVERY, 2022 0.87 [0.77; 0.98]
Tang X, 2020 0.98 [0.93; 1.02]
0.95 [0.87 ; 1.03 ] BACC Bay Tocilizumab Trial, 2020, LIFESAVER, 2021, RECOVERY, 2022, Tang X, 2020 4 23% 8,496 moderate not evaluable clinical deteriorationdetailed results BACC Bay Tocilizumab Trial, 2020 1.11 [0.59; 2.09]
Tang X, 2020 1.00 [0.13; 7.45]
1.10 [0.60 ; 2.01 ] BACC Bay Tocilizumab Trial, 2020, Tang X, 2020 2 0% 328 low not evaluable clinical improvementdetailed results BACC Bay Tocilizumab Trial, 2020 1.06 [0.80; 1.41]
Tang X, 2020 1.04 [0.67; 1.62]
1.05 [0.83 ; 1.34 ] BACC Bay Tocilizumab Trial, 2020, Tang X, 2020 2 0% 328 low not evaluable clinical improvement (14-day)detailed results Tang X, 2020 1.33 [0.57; 3.11]
1.33 [0.57 ; 3.11 ] Tang X, 2020 1 0% 86 NA not evaluable clinical improvement (time to event analysis only)detailed results Tang X, 2020 1.04 [0.67; 1.62]
1.04 [0.67 ; 1.62 ] Tang X, 2020 1 0% 86 NA not evaluable death or ventilationdetailed results BACC Bay Tocilizumab Trial, 2020 0.83 [0.38; 1.81]
RECOVERY, 2022 0.90 [0.81; 0.99]
0.90 [0.81 ; 0.99 ] BACC Bay Tocilizumab Trial, 2020, RECOVERY, 2022 2 0% 8,147 moderate not evaluable mechanical ventilationdetailed results RECOVERY, 2022 0.87 [0.74; 1.02]
0.87 [0.74 ; 1.02 ] RECOVERY, 2022 1 0% 7,905 NA not evaluable viral clearance detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable viral clearance (time to event analysis only)detailed results Tang X, 2020 1.78 [1.06; 3.00]
1.78 [1.06 ; 3.00 ] Tang X, 2020 1 0% 86 NA not evaluable ICU admissiondetailed results Tang X, 2020 1.00 [0.13; 7.45]
1.00 [0.13 ; 7.45 ] Tang X, 2020 1 0% 86 NA not evaluable serious adverse eventsdetailed results BACC Bay Tocilizumab Trial, 2020 1.21 [0.58; 2.53]
1.21 [0.58 ; 2.53 ] BACC Bay Tocilizumab Trial, 2020 1 0% 242 NA not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 15:25 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 94
- treatments: 546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525
- roots T: 290
